Tumor News and Research

RSS

Discovery may lead to new treatments for common autoimmune diseases

Researchers at the University of Georgia report in the Journal of Biological Chemistry that an enzyme known as Tumor Progression Locus 2, or Tpl2, plays a key role in directing and regulating several important components of the body's immune system.

17 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

16 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Submicroscopic particles could make MRI far more powerful tool to detect disease

Submicroscopic particles that contain even smaller particles of iron oxide could make magnetic resonance imaging (MRI) a far more powerful tool to detect and fight disease.

16 Jun 2014

Risk of breast cancer recurrence associated with carbohydrate intake

Dartmouth researchers have found that reducing carbohydrate intake could reduce the risk of breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor.

13 Jun 2014

New class of tumor-targeting agents can seek out dozens of solid tumors

Scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments.

13 Jun 2014

New imaging software measures growth of nodules in patients at risk of lung cancer

Medical-imaging software under development at Rochester Institute of Technology could someday give radiologists a tool for measuring the growth of nodules in patients at risk of lung cancer, the leading cause of cancer deaths in the United States, according to the Center for Disease Control and Prevention.

13 Jun 2014

Low cholesterol may increase mortality risk in patients with kidney cancer

People are often told to reduce their cholesterol to improve their heart health, but new research suggests that low cholesterol may increase kidney cancer patients' risk of dying from their disease. The findings, which are published in BJU International, indicate that cholesterol testing may help doctors as they monitor and treat patients with kidney cancer.

12 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Reducing carbohydrate intake could reduce risk of breast cancer recurrence

Dartmouth researchers have found that reducing carbohydrate intake could reduce the risk of breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor. The study, "Risk of Breast Cancer Recurrence Associated with Carbohydrate Intake and Tissue Expression of IGFI Receptor," will appear in the July issue of Cancer Epidemiology Biomarkers & Prevention.

11 Jun 2014

Conventional proton radiotherapy to fight against cancer

The future face of modern-day anti-cancer therapy based on charged particles like protons could potentially involve using laser accelerators. However, these facilities will need to be reduced in terms of both size and cost compared to conventional ones.

11 Jun 2014

Researchers discover new class of tumor

This is the story of two perfectly harmless genes. By themselves, PAX3 and MAML3 don't cause any problems. However, when they combine during an abnormal but recurring chromosomal mismatch, they can be dangerous.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Tumor News and Research

Discovery may lead to new treatments for common autoimmune diseases

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

Submicroscopic particles could make MRI far more powerful tool to detect disease

Risk of breast cancer recurrence associated with carbohydrate intake

New class of tumor-targeting agents can seek out dozens of solid tumors

New imaging software measures growth of nodules in patients at risk of lung cancer

Low cholesterol may increase mortality risk in patients with kidney cancer

Cancer drug offers protection against thrombosis

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Reducing carbohydrate intake could reduce risk of breast cancer recurrence

Conventional proton radiotherapy to fight against cancer

Researchers discover new class of tumor

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Celsion signs definitive asset purchase agreement to acquire EGEN

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News